Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for progressive supranuclear palsy: past and future

D G Cole1, J H Growdon

  • 1Department of Neurology, Massachusetts General Hospital, Charlestown.

Journal of Neural Transmission. Supplementum
|January 1, 1994
PubMed
Summary

Idazoxan (IDA), an adrenergic agonist, improved balance and manual dexterity in about half of progressive supranuclear palsy (PSP) patients. This suggests targeting brain structures outside the basal ganglia may offer new symptomatic treatments for PSP.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases.

NeuroImage. Clinical·2015
Same author

A Neural Dissociation within Language: Evidence that the Mental Dictionary Is Part of Declarative Memory, and that Grammatical Rules Are Processed by the Procedural System.

Journal of cognitive neuroscience·2013
Same author

Imaging amyloid deposition in Lewy body diseases.

Neurology·2008
Same author

Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study.

Neurology·2008
Same author

White matter pathology isolates the hippocampal formation in Alzheimer's disease.

Neurobiology of aging·2008
Same author

Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease.

Neuro-degenerative diseases·2007

Area of Science:

  • Neuroscience
  • Neurology
  • Pharmacology

Background:

  • Progressive supranuclear palsy (PSP) involves dysfunction across multiple brain systems, complicating treatment.
  • Previous neurotransmitter replacement strategies targeting dopaminergic, cholinergic, and serotonergic systems have failed in PSP.
  • The cortico-striato-pallidal loop is degenerated in PSP, necessitating alternative therapeutic targets.

Purpose of the Study:

  • To investigate the efficacy of idazoxan (IDA), an adrenergic agonist, in treating progressive supranuclear palsy (PSP).
  • To explore therapeutic strategies targeting brain structures outside the basal ganglia for symptomatic relief in PSP.

Main Methods:

  • Two randomized, double-blind, placebo-controlled, crossover studies were conducted.
  • Patients with PSP were administered idazoxan (IDA) or a placebo.

Related Experiment Videos

  • Improvements in balance and manual dexterity were assessed.

    • Main Results:

    • Approximately 50% of patients showed statistically significant improvements in balance and manual dexterity with IDA compared to placebo.
    • Idazoxan demonstrated potential as a symptomatic treatment for PSP.

    Conclusions:

    • Targeting brain structures outside the basal ganglia may provide effective symptomatic treatment for PSP.
    • Further research into the underlying pathology of PSP is crucial for developing disease-modifying therapies.